Human peroxisome proliferator activated receptor γ

Abstract

The present invention relates to a novel human peroxisome proliferator activated receptor, hPPARγ. hPPARγ differs from the mouse peroxisome proliferator activated receptor γ in the nucleotide sequence and the amino acid sequence. The invention provides isolated, purified, enriched or recombinant nucleic acid encoding hPPARγ polypeptides and vectors containing thereof, cells transformed with such vectors, and methods of screening for agonists and antagonists of hPPARγ polypeptides. The invention also provides isolated, purified, enriched, or recombinant hPPARγ polypeptides, antibodies having specific binding affinity to hPPARγ polypeptides, and hybridomas producing such antibodies.

1. An isolated nucleic acid comprising a contiguous nucleic acid sequence encoding SEQ ID NO: 2 and an operably linked promoter. 
     
     
       2. The nucleic acid of  claim 1 , wherein the contiguous nucleic acid sequence consists of nucleotide 157 to 1641 of SEQ ID NO: 1 or its fully complementary strand of the same length. 
     
     
       3. An isolated nucleic acid comprising a contiguous nucleic acid sequence encoding amino acid residue 18 to 494 of SEQ ID NO: 2 and an operably linked promoter. 
     
     
       4. The nucleic acid of  claim 3 , wherein the contiguous nucleic acid sequence consists of nucleotide 208 to 1641 of SEQ ID NO: 1 or its fully complementary strand of the same length. 
     
     
       5. An isolated nucleic acid comprising a contiguous nucleic acid sequence encoding amino acid residue 20 to 494 of SEQ ID NO: 2 and an operably linked promoter. 
     
     
       6. The nucleic acid of  claim 5 , wherein the contiguous nucleic acid sequence consists of nucleotide 214 to 1641 of SEQ ID NO: 1 or its fully complementary strand of the same length. 
     
     
       7. An isolated nucleic acid comprising a contiguous nucleic acid sequence encoding SEQ ID NO: 2. 
     
     
       8. The nucleic acid of  claim 7 , wherein the contiguous nucleic acid sequence consists of nucleotide 157 to 1641 of SEQ ID NO: 1 or its fully complementary strand of the same length. 
     
     
       9. An isolated nucleic acid comprising a contiguous nucleic acid sequence encoding amino acid residue 18 to 494 of SEQ ID NO: 2. 
     
     
       10. The nucleic acid of  claim 9 , wherein the contiguous nucleic acid sequence consists of nucleotide 208 to 1641 of SEQ ID NO: 1 or its fully complementary strand of the same length. 
     
     
       11. An isolated nucleic acid comprising a contiguous nucleic acid sequence encoding amino acid residue 20 to 494 of SEQ ID NO: 2. 
     
     
       12. The nucleic acid of  claim 11 , wherein the contiguous nucleic acid sequence consists of nucleotide 214 to 1641 of SEQ ID NO: 1 or its fully complementary strand of the same length. 
     
     
       13. The nucleic acid of  claim 1 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       14. The nucleic acid of  claim 2 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       15. The nucleic acid of  claim 3 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       16. The nucleic acid of  claim 4 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       17. The nucleic acid of  claim 5 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       18. The nucleic acid of  claim 6 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       19. The nucleic acid of  claim 7 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       20. The nucleic acid of  claim 8 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       21. The nucleic acid of  claim 9 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       22. The nucleic acid of  claim 10 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       23. The nucleic acid of  claim 11 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       24. The nucleic acid of  claim 12 , wherein the nucleic acid is a recombinant nucleic acid. 
     
     
       25. A purified or enriched nucleic acid comprising a contiguous nucleic acid sequence encoding SEQ ID NO: 2. 
     
     
       26. The nucleic acid of  claim 25 , wherein the contiguous nucleic acid sequence consists of nucleotide 157 to 1641 of SEQ ID NO: 1 or its fully complementary strand of the same length. 
     
     
       27. A purified or enriched nucleic acid comprising a contiguous nucleic acid sequence encoding amino acid residue 18 to 494 of SEQ ID NO: 2. 
     
     
       28. The nucleic acid of  claim 27 , wherein the contiguous nucleic acid sequence consists of nucleotide 208 to 1641 of SEQ ID NO: 1 or its fully complementary strand of the same length. 
     
     
       29. A purified or enriched nucleic acid comprising a contiguous nucleic acid sequence encoding amino acid residue 20 to 494 of SEQ ID NO: 2. 
     
     
       30. The nucleic acid of  claim 29 , wherein the contiguous nucleic acid sequence consists of nucleotide 214 to 1641 of SEQ ID NO: 1 or its fully complementary strand of the same length. 
     
     
       31. The nucleic acid of  claim 25 , further comprising a promoter operably linked to the contiguous nucleic acid sequence. 
     
     
       32. The nucleic acid of  claim 26 , further comprising a promoter operably linked to the contiguous nucleic acid sequence. 
     
     
       33. The nucleic acid of  claim 27 , further comprising a promoter operably linked to the contiguous nucleic acid sequence. 
     
     
       34. The nucleic acid of  claim 28 , further comprising a promoter operably linked to the contiguous nucleic acid sequence. 
     
     
       35. The nucleic acid of  claim 29 , further comprising a promoter operably linked to the contiguous nucleic acid sequence. 
     
     
       36. The nucleic acid of  claim 30 , further comprising a promoter operably linked to the contiguous nucleic acid sequence.